Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Factor Bioscience Inc. has 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These are distributed among 5 distinct examiners and 3 distinct art units. This spread indicates that the company's biotechnology filings are being reviewed by several different individuals across a few specialized groups. The involvement of 3 distinct art units suggests that practitioners must navigate multiple sets of internal practices within the Biotechnology & Pharmaceuticals sector.
LEONARD, ARTHUR S is the busiest examiner, with 1 pending office action. This highlights that each of the 5 pending office actions is being handled by a different distinct examiner. This distribution suggests that the company's intellectual property in this sector touches on varied technical sub-specialties rather than being concentrated under a single supervisory group. Practitioners should prepare for diverse examination styles given that the 3 distinct art units likely apply different internal guidelines or prior art preferences for the 5 pending office actions.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| Double-patenting only | 1 (20%) |
| Double-patenting + other | 2 (40%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEONARD, ARTHUR S | 1 | 50.8% | +50.2% |
| NOBLE, MARCIA STEPHENS | 1 | 67.0% | +39.9% |
| VANHORN, ABIGAIL LOUISE | 1 | 46.8% | +22.4% |
| ZHU, JIANJIAN | 1 | 58.8% | +82.4% |
| FOX, ALLISON M | 1 | 71.2% | +35.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18046787 | MESENCHYMAL STEM CELL THERAPIES | FOX, ALLISON M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18461368 | ENGINEERED IMMUNE CELL THERAPIES | VANHORN, ABIGAIL LOUISE | 9d overdue |
| 18328598 | NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF | ZHU, JIANJIAN | 22d |
| 18980218 | METHODS AND PRODUCTS FOR NUCLEIC ACID PRODUCTION AND DELIVERY | LEONARD, ARTHUR S | — |
| 18913757 | METHODS AND PRODUCTS FOR TRANSFECTION | NOBLE, MARCIA STEPHENS | — |
| 18046787 | MESENCHYMAL STEM CELL THERAPIES | FOX, ALLISON M | — |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| 1631 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18980218 | METHODS AND PRODUCTS FOR NUCLEIC ACID PRODUCTION AND DELIVERY | LEONARD, ARTHUR S | — | §102§103§112DP | Non-Final OA | — | Pending | Dec 13, 2024 |
| 18913757 | METHODS AND PRODUCTS FOR TRANSFECTION | NOBLE, MARCIA STEPHENS | — | DP | Non-Final OA | — | Pending | Oct 11, 2024 |
| 18461368 | ENGINEERED IMMUNE CELL THERAPIES | VANHORN, ABIGAIL LOUISE | 1636 | §103§112DP | Final Rejection | 9d overdue | Pending | Sep 05, 2023 |
| 18328598 | NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF | ZHU, JIANJIAN | 1631 | §103 | Final Rejection | 22d | Pending | Jun 02, 2023 |
| 18046787 | MESENCHYMAL STEM CELL THERAPIES | FOX, ALLISON M | 1633 | §102§103§112 | Non-Final OA | — | Pending | Oct 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial